Colorectal
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Emerging exposure-driven accelerated colorectal carcinogenesis: a model with implications for screening colonoscopy effectiveness.
Clinical takeawayNo clinical action yet: a conceptual model proposing mechanisms for accelerated CRC development, not yet tested in humans.
What it foundProposes a model where environmental and lifestyle exposures accelerate colorectal carcinogenesis, potentially bypassing conventional precursor stages.
ContextChallenges the traditional slow-progression model of CRC, suggesting some cases may arise too rapidly for current screening to prevent.
Emergingsuggested applicable standard· U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017
Decision at stakethe need to consider exposure-driven accelerated carcinogenesis in colorectal cancer screening strategies
U.S. Multi-Society Task Force on Colorectal Cancer (Rex DK, Boland CR, Dominitz JA, et al.), "Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer," Gastroenterology, 2017 · reviewed 2026-07-23 ↗Begin average-risk colorectal cancer screening at age 45 using a patient-centered shared-decision modality choice, colonoscopy every 10 years (preferred) or annual FIT as Tier 1 options, with multi-target stool DNA every 3 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 to 10 years as Tier 2 alternatives. A positive stool-based test requires diagnostic colonoscopy, and stool tests should not be ordered for patients who would decline follow-up colonoscopy. Generally stop at age 75 with individualized decisions for ages 76-85 and no screening beyond 85.
Truninger K … Fazilaty H · Gut · IF 24.6 · PubMed ↗